

Freedom of Information Request Reference

I am researching the incidence and treatment of breast cancer. Could you please provide the number of patients that you have treated in the past three months with the following:

- **Abemaciclib + Anastrozole/Exemestane/Letrozole**
- **Abemaciclib + Fulvestrant**
- **Alpelisib + Fulvestrant**
- **Atezolizumab**
- **Bevacizumab**
- **Eribulin**
- **Everolimus + Exemestane**
- **Fulvestrant as a single agent**
- **Gemcitabine + Paclitaxel**
- **Lapatinib**
- **Neratinib**
- **Olaparib**
- **Palbociclib + Anastrozole/Exemestane/Letrozole**
- **Palbociclib + Fulvestrant**
- **Pertuzumab + Trastuzumab + Docetaxel**
- **Ribociclib + Anastrozole/Exemestane/Letrozole**
- **Ribociclib + Fulvestrant**
- **Talazoparib**
- **Transtuzumab + Paclitaxel**
- **Transtuzumab as a single agent**
- **Trastuzumab emtansine**
- **Any other active systemic anti-cancer therapy**

Regime	Number of patients
Abemaciclib + Anastrozole/Exemestane/Letrozole	1
Abemaciclib + Fulvestrant	2
Alpelisib + Fulvestrant	0
Atezolizumab	1
Bevacizumab	0
Eribulin	2
Everolimus + Exemestane	0
Fulvestrant as a single agent	9
Gemcitabine + Paclitaxel	0
Lapatinib	0
Neratinib	0
Olaparib	0
Palbociclib + Anastrozole/Exemestane/Letrozole	13
Palbociclib + Fulvestrant	2
Pertuzumab + Trastuzumab + Docetaxel	14
Ribociclib + Anastrozole/Exemestane/Letrozole	0
Ribociclib + Fulvestrant	0
Talazoparib	0
Trastuzumab + Paclitaxel	2
Trastuzumab as a single agent	19
Trastuzumab emtansine	2
All other SACT	39